A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors

Conditions:   Basal Cell Carcinoma;   Medulloblastoma;   Adenocarcinoma of Esophagogastric Junction;   Small Cell Lung Cancer;   Neuroendocrine Neoplasm;   Glioblastoma Intervention:   Drug: ZSP1602 Sponsor:   Guangdong Zhongsheng Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials